Century Therapeutics, Inc.
Century Therapeutics, Inc. (IPSC) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
ipsc · stock forecast · 9 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 9 Wall Street analysts in the past 3 months
Buy
9 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$4.00
Consensus
$3.00
+41.5% upside
Low
$2.00
Median: $3 · Last Close: $2.12
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$3.00
41.5% upside
High Target
$4
88.7%
Low Target
$2
-5.7%
Current Price
$2.12
as of today
Based on analyst price targets, the IPSC stock price prediction for the next 12 months ranges from $2 to $4. The consensus IPSC price forecast of $3.00 implies 41.5% upside from the current price of $2.12.
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $2.06 | ↓ 3.06% |
1-day model range: $2.02–$2.09. Peak: $2.09 (-3.06%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · IPSC · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-04-21 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-01-20 | Piper Sandler | Maintains | Overweight→Overweight |
| 2025-11-17 | Leerink Partners | Downgrade ↓ | Outperform→Market Perform |
| 2025-05-16 | Chardan Capital | Maintains | Buy→Buy |
| 2025-04-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-28 | Guggenheim | Maintains | Buy→Buy |
| 2025-03-24 | Chardan Capital | Maintains | Buy→Buy |
| 2025-03-21 | Guggenheim | Maintains | Buy→Buy |
| 2025-03-20 | Piper Sandler | Maintains | Overweight→Overweight |
| 2025-01-22 | Guggenheim | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Century Therapeutics, Inc. (IPSC) stock. Of the recent 38 rating actions, 0 were upgrades and 2 were downgrades. 9 analysts currently cover IPSC.
Analyst Recommendation Trends
IPSC analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 4 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$5M
↑ 300.2% YoY
Revenue Next Year
$4M
↓ 20.9% YoY
EPS This Year
$-0.46
EPS Next Year
$-0.45
↓ 2.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast IPSC EPS of $-0.46 for the current fiscal year, based on estimates from 3 analysts. The IPSC revenue forecast is $5M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The IPSC stock forecast is supported by two independent data sources: analyst consensus ratings from 9 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus IPSC price target is $3.00 (+41.5% upside), with an analyst consensus of Buy.
The IPSC short-term stock prediction for tomorrow is $2.06 (-3.06%).
Century Therapeutics, Inc. trades on NASDAQ under the ticker IPSC. The IPSC stock outlook for 2027 is broadly positive, supported by a Buy consensus among 78% of covering analysts.
Frequently asked questions
IPSC forecast · 8 questionsAccording to 9 Wall Street analysts, the average 12-month IPSC price target is $3.00, with a high forecast of $4.00 and a low of $2.00. The median price target is shown in the chart above when available. This implies +41.5% potential upside from the current price of $2.12.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.